NLRP3 and Myocardial fibrosis: Our study has shown that by reducing the expression of these proteins, treatment with PF can mitigate the left ventricular remodeling induced by AMI under persistent hypobaric hypoxia by counteracting inflammation, myocardial fibrosis, and apoptosis triggered by the NLRP3 inflammasome.